Stocks

Merck & Co's Price Target Raised to $170.00 as Analyst Maintains 'Buy' Rating

Guavy AI Editorial Team Published August 25, 2026

Instruments

MRK

Argus Research analyst Jasper Hellweg has maintained a 'Buy' rating for Merck & Co (MRK) while raising the price target from $145.00 to $170.00, reflecting a significant increase of 17.24%. This upgrade comes after reviewing Merck's robust product pipeline and market position.

The company operates in the healthcare sector with a market capitalization of approximately $371.7 billion, making it a major player in pharmaceuticals, vaccines, and biologic therapies.

According to GuruFocus, Merck & Co is currently overvalued by 25.6%, as its current price ($150.66) exceeds its intrinsic value ($119.94). The price-to-earnings (P/E) ratio for MRK stands at 120.53x, which is significantly higher than its 5-year median P/E of 20.38x.

Merck & Co's Price Target Raised to $170.00 as Analyst Maintains 'Buy' Rating

Disney Offers Voluntary Early Retirement Packages to Select Executives Amid Cost-Cutting Efforts

EPCOT Dominates Hollywood Studios in Disney After Hours Event

Disney Cruise Line Returns with Exciting Fall 2027 and Spring 2028 Itineraries